Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Bard Financial Services Inc.

Bard Financial Services Inc. lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.2% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 28,845 shares of the biopharmaceutical company’s stock after selling 1,250 shares during the period. Bard Financial Services Inc.’s holdings in Gilead Sciences were worth $3,232,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Brighton Jones LLC lifted its holdings in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares during the period. Golden State Wealth Management LLC purchased a new stake in Gilead Sciences during the fourth quarter valued at about $70,000. Kestra Private Wealth Services LLC lifted its stake in Gilead Sciences by 4.4% during the fourth quarter. Kestra Private Wealth Services LLC now owns 29,368 shares of the biopharmaceutical company’s stock valued at $2,713,000 after buying an additional 1,247 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter valued at about $33,000. Finally, Angeles Wealth Management LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at about $200,000. Institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total value of $249,550.00. Following the sale, the chief financial officer now owns 165,674 shares in the company, valued at approximately $16,537,578.68. The trade was a 1.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $110.42, for a total value of $1,104,200.00. Following the sale, the chief executive officer now owns 620,268 shares in the company, valued at approximately $68,489,992.56. This represents a 1.59% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,000 shares of company stock worth $4,630,310. 0.27% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on GILD shares. Piper Sandler increased their price objective on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. The Goldman Sachs Group increased their price objective on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Morgan Stanley raised their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, April 25th. Wells Fargo & Company increased their price objective on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Finally, Cantor Fitzgerald began coverage on Gilead Sciences in a report on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 price objective for the company. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $110.55.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $110.09 on Wednesday. The firm has a market capitalization of $136.94 billion, a P/E ratio of 297.54, a PEG ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a 1 year low of $62.69 and a 1 year high of $119.96. The business has a 50-day moving average of $105.36 and a 200-day moving average of $101.86. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company’s revenue for the quarter was down .3% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.32) EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.87%. Gilead Sciences’s payout ratio is currently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.